dm+d

Unassigned

New Medicines

Haemorrhage following total knee arthroplasty

Information

New molecular entity
Thrombotargets
Thrombotargets

Development and Regulatory status

None
Phase III Clinical Trials
None
Feb 21No apparent development since 2018 when PII/III HESTAT trial (NCT02687399) record was last updated

Category

Yeast-derived microvesicles containing glycosylated recombinant human tissue factor, formulated as a room temperature-stable lyophilisate for suspension and a powder for reconstitution
TKA involves extensive soft tissue release & bone incisions, resulting in significant blood loss. Allogenic blood transfusions are generally used to prevent postoperative anaemia but are associated with additional risks, e.g. transmission of infectious disease, transfusion-related acute lung injury, haemolytic reactions, fluid overload, increased rate of postop infection, and immunosuppression [1]. Total number of TKAs in England, Wales & Northern Ireland was 106,334 in 2017 [2].
Haemorrhage following total knee arthroplasty
Topical